US Obesity Prevalence: CDC State and Demographic Data

Forty-two percent of American adults have obesity. That is not a niche health issue. It is a defining feature of the contemporary health landscape. Yet despite the scale of the problem, fewer than 1 in 100 adults with obesity who are eligible for medical treatment actually receive it. This gap between need and access is the core problem that Transformation Health was built to address.

This page summarizes the most recent CDC and NHANES data on obesity prevalence, who is most affected, where rates are highest, and the economics and health impacts of untreated obesity. It is designed as a reference for patients researching their own situation, and as context for understanding why telehealth access to weight management medications matters.

National Obesity Prevalence Data

Based on the most recent National Health and Nutrition Examination Survey (NHANES) data from the CDC, approximately 42-43% of US adults have obesity, defined as a BMI of 30 or greater^[1]. An additional 31-32% are overweight (BMI 25 to 29.9). Combined, roughly 73-74% of American adults fall outside the healthy weight range. This is not an outlier finding. These rates have remained consistent in recent CDC surveillance data from 2022-2023.

Severe obesity, defined as a BMI of 40 or above, affects 9-10% of the US adult population. This category has grown especially rapidly over the past two decades, reflecting a shift not just toward higher average weights but toward more substantial weight gain.

The Upward Trend: Obesity Has Doubled Since 2000

The prevalence of obesity in the United States has not been stable. It has increased substantially over the past 25 years. According to NHANES data, obesity prevalence was approximately 30.5% in 1999-2000. By 2017-2018, it had reached 42.4%^[2]. The trend has continued upward in the years since.

This represents a gain of more than 12 percentage points in fewer than two decades. At the same time, severe obesity has grown even faster, rising from 4.7% to 9.2% of the adult population over the same period. This pattern tells us that the problem is not just that more people have obesity, but that the distribution of body weight has shifted, with more adults in higher weight categories.

Who Is Most Affected: Demographics

Obesity prevalence is not evenly distributed across demographic groups. Understanding who is most affected is important for several reasons: it shapes public health priorities, it influences who has greatest access barriers, and it directly affects patient decisions about whether treatment is “for them.”

By Sex

Men and women experience obesity at nearly equivalent rates. Approximately 41% of men have obesity, and approximately 44% of women have obesity, based on recent CDC data. The differences between sexes are not large, but they do vary by age group and regional factors. Age-related factors, particularly perimenopause and menopause in women, can influence the trajectory, but baseline obesity prevalence is comparable.

By Age

Obesity prevalence is highest among middle-aged adults, specifically those between 40 and 59 years old. This age group has an obesity rate of approximately 46%. Adults aged 20-39 have slightly lower rates (~41%), and adults aged 60 and older have slightly lower rates (~41%) as well. The peak in middle age reflects multiple factors: longer cumulative exposure to weight-promoting environments, metabolic changes with aging, hormonal transitions (particularly perimenopause), and reduced physical activity over time relative to younger adults.

By Race and Ethnicity

There are significant disparities in obesity prevalence by race and ethnicity, and these disparities are important to understand as part of the broader context of health equity.

Black adults have the highest obesity prevalence at approximately 50%. Hispanic adults have an obesity prevalence of approximately 45%. White adults have an obesity prevalence of approximately 41%. Asian Americans have the lowest prevalence at approximately 17%^[3].

These disparities are not the result of individual behavioral differences. They reflect complex structural factors: access to affordable, nutritious food; safe spaces for physical activity; healthcare quality and trust; stress and chronic adversity; and the legacies of systemic inequality. When we discuss who has obesity, we must also discuss why, and obesity prevalence data is inseparable from discussions of health equity and access.

By Education Level

Obesity prevalence is inversely related to education level, meaning that adults with higher levels of educational attainment have lower obesity rates than those with lower educational attainment. This relationship has been documented consistently across decades of CDC data. The causes are multifaceted: higher education often correlates with higher income, which can increase access to high-quality nutrition and fitness resources. Education itself provides health literacy that may support informed decision-making about diet and lifestyle. However, this relationship is not purely about individual knowledge, it reflects broader access barriers.

State-by-State Variation

Obesity prevalence varies significantly by state. The variation reflects differences in food environment, built environment (pedestrian infrastructure, parks, fitness facilities), healthcare access, economic factors, and others.

States with the Lowest Obesity Rates

Colorado has the lowest obesity prevalence among US states, at approximately 23%. Hawaii follows at approximately 24%, and Massachusetts at approximately 26%. California is at approximately 27%. These states have some combination of higher incomes, more walkable/bicycle-friendly infrastructure, greater access to healthcare, and cultural factors that support physical activity. However, even the lowest-obesity states still have at least 1 in 4 adults with obesity.

States with the Highest Obesity Rates

The highest obesity prevalence is found primarily in the Southeast and Appalachian regions.

West Virginia has the highest obesity rate at approximately 41% of adults. Mississippi is close behind at approximately 40%. Arkansas, Louisiana, and Alabama all have obesity prevalence of approximately 38-39%. Oklahoma, Texas, and Kentucky follow with rates in the 35-37% range.

This geographic clustering is not random. It reflects historical patterns of industrial decline, economic hardship, food deserts, limited access to preventive healthcare, and higher prevalence of chronic stress. Understanding obesity as a public health problem means understanding the structural factors that make certain regions more vulnerable.

Health Impact and Disease Association

Obesity is a medical condition that increases risk for multiple serious chronic diseases. These are not moral consequences of obesity, they are physiological ones. Adults with obesity have elevated risk for:

• Type 2 diabetes (obesity is the primary modifiable risk factor for type 2 diabetes onset)
• Cardiovascular disease, including hypertension and high cholesterol
• Sleep apnea (often severe, disrupting sleep and oxygen levels)
• Certain cancers, including breast, colorectal, and endometrial cancers
• Nonalcoholic fatty liver disease, which can progress to cirrhosis
• Osteoarthritis, due to excess load on joints
• Stroke
• Metabolic syndrome

The relationship between obesity and these conditions is not about willpower or discipline, it is biological. Excess adipose tissue (fat) is metabolically active. It produces inflammatory cytokines, impairs insulin signaling, and disrupts hormonal regulation. At the population level, obesity is a primary driver of preventable disease burden in the United States.

Economic Impact

The economic costs of obesity-related disease are substantial. According to CDC estimates from 2019, obesity-related medical costs in the United States are approximately 173 billion dollars annually^[4]. These costs accrue across the healthcare system: hospitalizations, emergency department visits, office-based care, medications, and long-term care for obesity-related complications.

At the individual level, adults with obesity have approximately 1,861 dollars in higher annual medical costs compared to adults with a healthy weight. Over the course of a working lifetime, this compounds to a significant financial burden, borne both by patients themselves and by the healthcare system as a whole.

The Treatment Gap: Why So Few People Receive Care

Despite the massive prevalence of obesity and its substantial health and economic impact, treatment remains inaccessible to the vast majority of eligible adults. Only approximately 1-2% of clinically eligible adults with obesity receive any form of medical treatment for it^[5]. This gap is the defining feature of obesity care in the United States.

Why the Gap Exists

Multiple overlapping factors drive this treatment gap.

Cost and insurance coverage: Many insurance plans do not cover weight management medications, or they cover them only for patients with specific comorbidities and high BMI thresholds. Uninsured and underinsured patients face the full cost of medications and provider care. Without insurance or discounted pharmacy programs, GLP-1 medications from major manufacturers can cost 900-1,500 dollars per month, placing them out of reach for most people.

Provider familiarity and stigma: Many primary care providers do not regularly prescribe weight management medications. The cultural narrative that obesity is a personal failure rather than a medical condition has shaped medical education and practice. Patients encounter stigma not only in the broader culture but sometimes in clinical settings themselves, which discourages them from seeking care.

Geographic access: Obesity specialists are concentrated in urban centers. Patients in rural communities may have limited access to providers trained in weight management, and travel barriers may make specialist care impractical.

Appointment availability and wait times: Many weight management programs have long waitlists. Patients who reach out may face months-long delays before seeing a provider.

Lack of awareness: Many adults with obesity do not realize that medical treatment is an option available to them. The narrative has historically centered on diet and exercise as the only “legitimate” interventions, even when those approaches have failed.

These barriers are not individual failures. They are systemic barriers, and they disproportionately affect certain populations, including those with lower incomes, those without insurance, those in rural areas, and communities of color.

The Role of GLP-1 Medications in Closing the Gap

GLP-1 medications (semaglutide, tirzepatide) have been demonstrated in clinical trials to reduce appetite, slow stomach emptying, and support sustained weight loss when combined with nutrition and lifestyle support. They are prescribed by licensed providers and are appropriate for adults with obesity or overweight with weight-related comorbidities.

However, brand-name GLP-1 medications remain expensive and inaccessible to most uninsured and underinsured patients. This is where compounded formulations and telehealth models create an opportunity to expand access.

How Telehealth Addresses Access Barriers

Telehealth weight management services, when paired with compounded medications and all-inclusive pricing, address several of the core barriers:

Geography: A patient in rural Montana can complete an online intake, have their information reviewed by a licensed provider, and receive medication shipped to their door. They never need to travel to a specialist office.

Cost and insurance: All-inclusive programs that bundle medication, provider care, labs, and coaching into a single monthly fee make the economics transparent and often more affordable than the combination of separate bills. For uninsured patients, cash-pay programs eliminate the insurance coverage barrier entirely.

Appointment availability: Asynchronous intake models allow patients to start within days rather than waiting months.

Provider access: Telehealth platforms connect patients with licensed providers who specialize in weight management, rather than relying on local provider availability.

Stigma reduction: Receiving care in your own home may reduce the stigma some patients experience in traditional clinical settings.

Understanding Transformation Health’s Role in This Context

Transformation Health is a technology platform that connects patients with independent, US-licensed providers. All clinical decisions, including prescription decisions, are made by these independent providers, not by Transformation Health itself.

The program’s all-inclusive pricing model, starting at 249 dollars per month for semaglutide and 339 dollars per month for tirzepatide, is designed for patients who do not have insurance coverage for weight management but want medically supervised treatment. The fee includes the medication (prepared by a US-based, licensed compounding pharmacy), all required lab work, provider consultations and ongoing care, and medical weight loss coaching.

This model exists specifically to serve the gap population: adults with obesity who are clinically appropriate for treatment, who have access barriers (uninsured, underinsured, geographic, or others), and who are motivated but have been unable to access care until now.

Citations

[1] CDC/NCHS. “National Health and Nutrition Examination Survey (NHANES): Obesity Data.” https://www.cdc.gov/nchs/nhanes/

[2] Stierman B, Afful J. “National Health Interview Survey Early Release Program.” CDC. https://www.cdc.gov/nchs/fastats/obesity-overweight.htm

[3] CDC. “Obesity Prevalence by Race and Ethnicity.” CDC Fast Stats. https://www.cdc.gov/nchs/fastats/obesity-overweight.htm

[4] CDC. “Obesity Costs.” CDC Obesity and Health Disparities. https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html

[5] Finkelstein EA, et al. “Obesity as a Disease in the U.S.: Prevalence and Health Effects.” Current Medical Research and Opinion. https://pubmed.ncbi.nlm.nih.gov/